New drug combo targets tough cancers in early trial
NCT ID NCT03891953
First seen Nov 10, 2025 · Last updated May 13, 2026 · Updated 21 times
Summary
This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and others that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. About 98 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Chuo Ku, Tokyo, 1040045, Japan
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.